Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ProstaScint prostate cancer imaging agent data

CYTO (Princeton, N.J.) reported preliminary Phase III findings at the meeting of the American Urologic Association in

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE